Once-weekly insulin icodec as novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials

Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study

(2023) Juan Frias et al.   Lancet Diabetes & Endocrinology

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

(2023) Juliana M. Bue-Valleskey et al.   DIABETES CARE

Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes

(2023) Ildiko Lingvay et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

(2023) Chantal Mathieu et al.   LANCET

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

(2023) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial

(2023) Athena Philis-Tsimikas et al.   Lancet Diabetes & Endocrinology

Glycemic control and its associated factors in type 2 diabetes patients at Felege Hiwot and Debre Markos Referral Hospitals

(2022) Nigusie Gashaye Shita et al.   Scientific Reports

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2022) Melanie J. Davies et al.   DIABETES CARE

Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials

(2022) Awadhesh Kumar Singh et al.   Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials

(2022) Hikmat Permana et al.   Diabetes & Metabolic Syndrome-Clinical Research & Reviews

2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023

(2022) Nuha A. ElSayed et al.   DIABETES CARE

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

(2021) Harpreet S. Bajaj et al.   DIABETES CARE

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

(2021) Ildiko Lingvay et al.   DIABETES CARE

Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans

(2021) Thomas B. Kjeldsen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycaemic Control for People with Type 2 Diabetes Mellitus in Bangladesh - An urgent need for optimization of management plan

(2019) Afsana Afroz et al.   Scientific Reports

The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran

(2019) MR Shafie Pour et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes

(2016)   DIABETOLOGIA

Type 2 diabetes mellitus

(2015) Ralph A. DeFronzo et al.   Nature Reviews Disease Primers

Patient perspectives on once-weekly medications for diabetes

(2010) W. H. Polonsky et al.   DIABETES OBESITY & METABOLISM